Back to search

Article

Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate Cancer

2023-04-21

Abstract excerpt

<title>Abstract</title> <p>Background The objective of this study was to evaluate the prognostic value of early PSA decline following initiation of second-generation hormone therapy (2nd HT), namely abiraterone acetate or enzalutamide, in patients with taxane-refractory metastatic castrate-resistant prostate cancer (mCRPC) and evaluate utility of this metric in informing intensified surveillance/imaging protocol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d2068a98-a484-5aab-8fca-9a14ef147f56
DOI
10.21203/rs.3.rs-2819133/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerDOI 10.21203/rs.3.rs-2819133/v1
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.Semantic proximity
Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysisSemantic proximity
Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by EnzalutamideSemantic proximity
How the Management of Biochemical Recurrence in Prostate Cancer Will be Modified by the Concept of Anticipation and Incrementation of TherapySemantic proximity
Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative ReviewSemantic proximity
VALIDATION OF PROGRESS, A SIMPLE MACHINE-LEARNING DERIVED RISK STRATIFICATION SCORE FOR CASTRATION-RESISTANT PROSTATE CANCERSemantic proximity
Recent trends in the management of advanced prostate cancerSemantic proximity
A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.Semantic proximity
Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesSemantic proximity
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.Semantic proximity
Bone Pain Is Associated with Short Radiologic-Progression-Free Survival in Patients with Metastatic Castration-Sensitive Prostate CancerSemantic proximity
Select a neighboring publication to make it the new centre.